All In Biotech

Drug Trial Radar · NCT01543321

Xenazine in Late Dyskinetic Syndrome With Neuroleptics

Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial

Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

54

Actual

Start

May 14, 2012

Primary completion

May 18, 2017

Study completion Aug 2017

Sponsor

Lead sponsor
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Late dyskinetic syndrome with neuroleptics, or tardive dyskinesia, is the appearance of abnormal involuntary movements (AIM) in patients treated with antipsychotics for at least three months. This important public health issue arises for 15-20% of patients treated with neuroleptics, the most prescribed psychotropic drugs in mental disorders in France, and seriously impacts the patients' quality of life. In over 50% of cases, it is irreversible-that is to say that he will persist despite discontinuation of the offending drug. Risk factors have been described: the age and female gender are established, a higher dosage of antipsychotic, a long-term treatment, a psychiatric condition other than schizophrenia are likely risk factors, intermittent treatment, previous acute dyskinesia, neuroleptics or powerful, longer term use of corrective treatments including anticholinergics are still discussed. Apart from preventive treatment, which consists in using antipsychotics as being coerced, support is disappointing: the etiological treatment, which is to stop the offending antipsychotic, is effective only in less than 50% of cases, the syndrome is most often late irreversible. Must still have the possibility to interrupt the treatment, which is usually impossible in the risk of decompensation of the mental illness for which the neuroleptic was prescribed. Remains symptomatic treatment: functional neurosurgery is only for extreme cases, because it is not without risk, in terms of morbidity and mortality. So it's the medication that is most often offered: many drugs have been proposed, a direct result of the multiplicity of neurotransmitter systems implicated. However, in the vast majority of cases, this approach is disappointing not to say ineffective. The only exception is the tetrabenazine, marketed under the name of Xenazine®. Empirically, neurologists specializing in pathology of the movement are almost unanimous: its efficiency is very good, with good tolerance. Some preliminary studies have reinforced this impression. However, their level of evidence remains low and that is why the investigators propose to implement a prospective multicenter clinical trial, double-blind with placebo which will include two groups of 27 patients.

Conditions

  • Tardive Dyskinesia

Interventions

  • TetrabenazineDrug

    Treatment with tetrabenazine consists in: * 5-week titration to a maximum dose of 200 mg / day * 5 weeks at stable dose * 2 weeks in wash-out The treatment will be blinded for patients and investigators

  • PlaceboDrug

    Treatment with placebo consists in: * 5-week titration to a maximum dose of 200 mg / day * 5 weeks at stable dose * 2 weeks in wash-out The treatment will be blinded for patients and investigators

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in ESRS: Extrapyramidal Symptoms Rating ScaleTime frame: 10 weeks after randomization

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • CH Aix en Provence

    Aix-en-Provence, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Caen

    Caen, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • CHRU Lille

    Lille, France

  • CHU Limoges

    Limoges, France

  • CH des Charpennes

    Lyon, France

  • AP-HM Hopital de la Timone

    Marseille, France

  • CHU Montpellier

    Montpellier, France

  • CHU Nantes

    Nantes, France

  • CHU Nice

    Nice, France

  • CHRU de Nimes

    Nîmes, France

  • CHU Saint Antoine

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • CHU de Rennes

    Rennes, France

  • CHU Rouen

    Rouen, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse

    Toulouse, France

  • CHU Amiens

    Amiens, Picardie, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.